These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 22989914)
1. Bruton's tyrosine kinase: oncotarget in myeloma. Tai YT; Anderson KC Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914 [TBL] [Abstract][Full Text] [Related]
2. BTK inhibition in myeloma: targeting the seed and the soil. Edwards CM Blood; 2012 Aug; 120(9):1757-9. PubMed ID: 22936735 [No Abstract] [Full Text] [Related]
4. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860 [TBL] [Abstract][Full Text] [Related]
5. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Liu N; Hoogendoorn S; van de Kar B; Kaptein A; Barf T; Driessen C; Filippov DV; van der Marel GA; van der Stelt M; Overkleeft HS Org Biomol Chem; 2015 May; 13(18):5147-57. PubMed ID: 25849561 [TBL] [Abstract][Full Text] [Related]
6. Ibrutinib for the treatment of Waldenström macroglobulinemia. Chakraborty R; Kapoor P; Ansell SM; Gertz MA Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997 [TBL] [Abstract][Full Text] [Related]
7. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977 [TBL] [Abstract][Full Text] [Related]
8. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib. Liu L; Shi B; Wang X; Xiang H Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836 [TBL] [Abstract][Full Text] [Related]
9. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Argyropoulos KV; Palomba ML Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. Tam CS; Ou YC; Trotman J; Opat S Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123 [No Abstract] [Full Text] [Related]
11. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia. Furman RR; Luan Y; Bilotti E; Graef T Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188 [No Abstract] [Full Text] [Related]
13. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071 [TBL] [Abstract][Full Text] [Related]
14. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Brown JR Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200 [TBL] [Abstract][Full Text] [Related]
15. Ibrutinib therapy for lymphoplasmacytic lymphoma. Helber MJ; Moore JE; Williams AM; Meacham PJ; Rothberg PG; Zent CS Am J Hematol; 2017 Sep; 92(9):E542-E544. PubMed ID: 28543765 [No Abstract] [Full Text] [Related]
16. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207 [TBL] [Abstract][Full Text] [Related]
17. Ibrutinib in B lymphoid malignancies. Smith MR Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513 [TBL] [Abstract][Full Text] [Related]
18. Targets for Ibrutinib Beyond B Cell Malignancies. Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359 [TBL] [Abstract][Full Text] [Related]